Eli Lilly signs a $1.9B deal with Ascidian Therapeutics for RNA exon editing in genetic kidney disease. Plus Regeneron expands CytomX pact for $37M upfront and $2B in biobucks, Congress moves to restrict China biotech partnerships via the COINS Act, and FDA issues revised draft guidance on pre-approval payer communications.
Auto-generated from the episode script. Deal names link to their scorecard in the database.
Eli Lilly writes another billion-dollar check — $1.9 billion for Ascidian Therapeutics and its RNA exon editing platform, aimed squarely at genetic kidney disease.
Meanwhile Congress moves to wall off China biotech partnerships, the FDA rewrites the rules on pre-approval payer communications, and Regeneron doubles down where other pharmas walked away. This is The Pharma Closeout.
Welcome to The Pharma Closeout for Wednesday, June 3rd, 2026. I'm Alex Mercer.
And I'm Maya Patel. Let's get into it.
Today's lead — Lilly and Ascidian Therapeutics announced a research collaboration worth up to $1.9 billion to develop RNA exon editing therapeutics for genetic kidney diseases. Per the company's announcement, Lilly gets exclusive rights in exchange for an upfront payment, development and commercial milestones, and tiered royalties on global sales. Put this in the context of Lilly's quarter — they just closed deals for Orna, Centessa, Kelonia, and Ajax. Ascidian is the fifth major transaction, all in a span of weeks.
The modality distinction matters here. RNA exon editing replaces faulty sections of RNA to produce full-length, functional protein — this is not gene silencing and not permanent DNA cuts. But the tension is real: Ascidian's clinical proof-of-concept is intravitreal delivery for Stargardt disease. Kidney is a fundamentally different delivery problem. Lilly is paying up to $1.9 billion for a renal program that is, at best, preclinical.
Fair push. The deal structure does limit the downside — the bulk of that headline number is milestone-gated, not upfront. And with strong Q1 revenue growth year-over-year and full-year guidance raised meaningfully, Lilly has the balance sheet for platform bets at this scale without breaking stride. Let's bring in Marcus Webb on the deal architecture.
This is Lilly's fifth major acquisition or collaboration this quarter. The pattern is unmistakable — they're assembling a genetic medicine toolkit across modalities: RNA exon editing with Ascidian, in vivo CAR-T through Kelonia, circular RNA through Orna. Risk per deal is managed through milestone-heavy structures, but the aggregate commitment signals a thesis — that multi-modal genetic medicine is where the next wave of differentiation lives.
What the clinically inclined will note is that Ascidian presented first-in-human safety data from its STELLAR trial in Stargardt at ASGCT last month — the platform has human proof. The billion-dollar translational question is whether you can redirect an AAV-delivered exon editor from the subretinal space to the renal parenchyma and maintain therapeutic protein expression at levels that actually correct genetic nephropathies. That is not a given.
It's not. And it's exactly why nephrology is the right proving ground. These diseases are increasingly well-characterized genetically, patient populations are identifiable, and there's a genuine therapeutic void. If the exon editing platform delivers in kidney, it extends into neurological and neuromuscular disease — Ascidian already has preclinical work in repeat expansion disorders including Huntington's. Lilly isn't just buying a kidney program. They're buying optionality across an entire modality.
Now Lilly wasn't the only one writing checks today. Regeneron expanded its collaboration with CytomX Therapeutics with a substantial upfront payment, significant milestone potential, and options on multiple additional targets. They're pairing CytomX's Probody platform with Regeneron's Veloci-Bi technology to develop conditionally active bispecifics in oncology. What makes this striking: other pharma partners walked away from CytomX. Regeneron went the other direction entirely.
A telling signal. The Probody platform has had mixed partner retention, so Regeneron expanding rather than exiting suggests they're seeing preclinical activity that validates the masked-antibody approach — or the competitive field has thinned enough that the partnership economics improved considerably. For CytomX, this deal is existential. That $37 million upfront with the option structure is the kind of capital that keeps a platform company alive.
Quick hits. Alnylam signed its first AI-powered drug discovery deal with RNA specialist Inceptive. Axsome extended patent protection on Sunosi, pushing generic entry to 2040 — substantial IP runway for one of their two marketed products alongside Auvelity.
On Alnylam — Inceptive specializes in computational RNA design, so this is about speed: identifying and optimizing novel RNAi targets faster than traditional screening. As more competitors crowd into the RNAi space, speed to differentiated targets becomes the competitive moat.
Two more. Gilead partnered with Cencora to expand U.S. distribution of Yescarta and Tecartus at authorized treatment centers — tackling the persistent logistics bottleneck in CAR-T access. And Mineralys Therapeutics made a bold financial move: repurchasing all future royalty obligations owed to Tanabe Pharma for a substantial upfront payment plus additional commercial milestone payments. That clears the royalty overhang ahead of lorundrostat's PDUFA date, December 22nd.
Buying back royalties before you have approval is a pure confidence play. Mineralys is telling the market they expect lorundrostat to launch, and they want full economic ownership when it does. If they're right about uncontrolled hypertension demand, that total investment could look like a bargain within a couple of years of commercial launch.
One more worth flagging — Bristol Myers Squibb has completed a broad AI rollout across its workforce and is now shifting focus to managing the costs of that deployment. BMS was among the first large pharmas to push AI tools at enterprise scale, and the fact that they're already in the cost-optimization phase tells you how quickly the industry moved from pilot to production.
The test is whether the productivity gains justify the spend. BMS is essentially running the experiment every other large pharma is watching. If their cost-to-value math works, expect a wave of similar enterprise deployments across the sector by year-end.
On the regulatory front — the FDA published revised draft guidance today on manufacturer communications with payors about unapproved products and unapproved uses of approved products. Comments are open through August 3rd.
This codifies a statutory safe harbor for pre-approval payer engagement — a historically gray zone that kept legal teams up at night. The updated guidance includes new real-world evidence examples and clarifies what health economic data firms can and cannot share with insurers.
For anyone in medical affairs or market access, this is directly actionable. Clearer guardrails on pre-approval payer discussions should accelerate formulary planning for drugs approaching their PDUFA dates. The practical effect: commercial teams engage payors earlier in the launch cycle with less legal risk, which tightens the gap between approval and patient access.
Also worth noting on the regulatory front — a bipartisan group of lawmakers unveiled legislation adding biotechnology to the COINS Act. This would restrict U.S. pharma deals with Chinese companies, following recent partnerships involving Pfizer and Bristol Myers Squibb. The bill frames China's drugmaking progress as a national security concern.
The implications are specific. Summit's ivonescimab partnership with Akeso, Merck's China-licensed oncology assets — any company with a Chinese biotech collaboration now carries a legislative risk premium layered on top of the clinical and commercial risk they were already managing. This is a real escalation from BIOSECURE, which targeted contract manufacturing. The new bill goes after the pipeline partnerships themselves.
Looking ahead — June's PDUFA calendar is stacked. The marquee event, as we flagged Sunday, is Merck's WELIREG plus KEYTRUDA combination for renal cell carcinoma — a key plank in Merck's post-patent-cliff oncology strategy. Also on deck: ensitrelvir for COVID-19 post-exposure prophylaxis with a June 16th date, and cytisinicline for smoking cessation on June 20th — which per the NDA filing would be the first new pharmacotherapy in that indication since varenicline in 2006.
And the post-ASCO overhang is still settling. Summit Therapeutics slid on a sell-the-news reaction after ivonescimab overall survival data showed a one-third reduction in death risk versus chemotherapy — but the four-month absolute survival benefit stirred real debate about clinical significance. On the flip side, BioNTech drew a UBS upgrade after presenting late-stage oncology data for pumitamig and gotistobart. ASCO week is over, but the market is still sorting winners from losers.
And keep your eye on Europe. Lilly and Boehringer Ingelheim each slashed planned investments in Germany by at least a billion dollars today — a direct response to German healthcare reform. That's over $2 billion in combined pullback.
When two of the largest pharma investors in a market coordinate reductions simultaneously, that is not coincidence — it's a negotiating posture. And every European government weighing pricing reform is watching how Berlin responds.
That's your Pharma Closeout for Wednesday. From Lilly's $1.9 billion RNA editing bet to Regeneron's CytomX expansion, the FDA's payer guidance rewrite, and Congress redrawing the rules on China partnerships — this industry generates more inflection points per week than most sectors manage in a quarter. If this briefing saves you time, follow us on Spotify, Apple Podcasts, or wherever you listen, and drop us a rating. We're back tomorrow.
Have a good evening, everyone. See you tomorrow.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →